1.16
price up icon4.50%   0.05
after-market Handel nachbörslich: 1.20 0.04 +3.45%
loading
Schlusskurs vom Vortag:
$1.11
Offen:
$1.15
24-Stunden-Volumen:
1.83M
Relative Volume:
0.37
Marktkapitalisierung:
$134.43M
Einnahmen:
$257.24M
Nettoeinkommen (Verlust:
$-237.89M
KGV:
-0.4462
EPS:
-2.6
Netto-Cashflow:
$-175.17M
1W Leistung:
+4.50%
1M Leistung:
-30.12%
6M Leistung:
-14.07%
1J Leistung:
-43.69%
1-Tages-Spanne:
Value
$1.11
$1.23
1-Wochen-Bereich:
Value
$1.095
$1.39
52-Wochen-Spanne:
Value
$0.6603
$2.87

Coherus Biosciences Inc Stock (CHRS) Company Profile

Name
Firmenname
Coherus Biosciences Inc
Name
Telefon
(650) 649-3530
Name
Adresse
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
Name
Mitarbeiter
235
Name
Twitter
@coherus_bio
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
CHRS's Discussions on Twitter

Vergleichen Sie CHRS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CHRS
Coherus Biosciences Inc
1.16 134.43M 257.24M -237.89M -175.17M -2.60
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
482.28 124.20B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
697.05 76.60B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
651.30 39.57B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
271.00 34.95B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
117.14 28.08B 3.30B -501.07M 1.03B -2.1146

Coherus Biosciences Inc Stock (CHRS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-08-16 Herabstufung UBS Buy → Neutral
2023-11-17 Eingeleitet Robert W. Baird Outperform
2023-11-08 Herabstufung Maxim Group Buy → Hold
2023-07-24 Eingeleitet Citigroup Buy
2023-05-01 Eingeleitet Truist Buy
2023-03-28 Hochstufung UBS Neutral → Buy
2022-06-14 Eingeleitet UBS Neutral
2022-03-07 Herabstufung JP Morgan Overweight → Neutral
2020-07-16 Eingeleitet BofA Securities Neutral
2020-04-17 Eingeleitet SunTrust Buy
2019-08-13 Eingeleitet Mizuho Buy
2019-08-02 Bestätigt H.C. Wainwright Buy
2019-08-02 Bestätigt Maxim Group Buy
2019-06-11 Eingeleitet Barclays Overweight
2019-05-07 Eingeleitet H.C. Wainwright Buy
2018-08-28 Eingeleitet H.C. Wainwright Buy
2018-03-09 Bestätigt Maxim Group Buy
2017-08-08 Bestätigt JP Morgan Overweight
2017-06-13 Bestätigt Maxim Group Buy
2017-05-05 Eingeleitet BMO Capital Markets Outperform
2016-10-19 Eingeleitet Robert W. Baird Outperform
2016-09-07 Eingeleitet Maxim Group Buy
2016-07-27 Eingeleitet Citigroup Buy
2016-01-20 Eingeleitet Credit Suisse Outperform
Alle ansehen

Coherus Biosciences Inc Aktie (CHRS) Neueste Nachrichten

pulisher
Jan 24, 2025

Coherus BioSciences's SWOT analysis: stock faces headwinds amid oncology pivot - MSN

Jan 24, 2025
pulisher
Jan 23, 2025

Coherus BioSciences (NASDAQ:CHRS) Earns Buy Rating from HC Wainwright - MarketBeat

Jan 23, 2025
pulisher
Jan 22, 2025

Positive Phase II trial results for Coherus' casdozokitug - The Pharma Letter

Jan 22, 2025
pulisher
Jan 22, 2025

Coherus Presents Final Phase 2 Clinical Casdozokitug - GlobeNewswire

Jan 22, 2025
pulisher
Jan 22, 2025

Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with ... - The Bakersfield Californian

Jan 22, 2025
pulisher
Jan 21, 2025

CHRS (Coherus BioSciences) Market Cap : $160.1 Mil (As of Jan. 21, 2025) - GuruFocus.com

Jan 21, 2025
pulisher
Jan 08, 2025

Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Marketscreener.com

Jan 08, 2025
pulisher
Jan 08, 2025

Coherus BioSciences (NASDAQ:CHRS) Shares Cross Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat

Jan 08, 2025
pulisher
Dec 31, 2024

Coherus BioSciences (NASDAQ:CHRS) Stock Crosses Above 200-Day Moving AverageShould You Sell? - MarketBeat

Dec 31, 2024
pulisher
Dec 21, 2024

There's No Escaping Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Muted Revenues Despite A 38% Share Price Rise - Simply Wall St

Dec 21, 2024
pulisher
Dec 18, 2024

Coherus to Present Final Phase 2 Casdozokitug Combination - GlobeNewswire

Dec 18, 2024
pulisher
Dec 18, 2024

Coherus BioSciences to Present Groundbreaking Cancer Treatment Data at ASCO-GI 2025 - StockTitan

Dec 18, 2024
pulisher
Dec 16, 2024

Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development - Seeking Alpha

Dec 16, 2024
pulisher
Dec 16, 2024

Short Interest in Coherus BioSciences, Inc. (NASDAQ:CHRS) Drops By 7.0% - MarketBeat

Dec 16, 2024
pulisher
Dec 16, 2024

Coherus Biosciences' SWOT analysis: stock faces headwinds amid transition - Investing.com

Dec 16, 2024
pulisher
Dec 11, 2024

Coherus BioSciences, Inc. (NASDAQ:CHRS) Shares Sold by Jacobs Levy Equity Management Inc. - MarketBeat

Dec 11, 2024
pulisher
Dec 10, 2024

Coherus BioSciences to divest UDENYCA franchise for up to $558.4M - MSN

Dec 10, 2024
pulisher
Dec 10, 2024

Coherus BioSciences, Inc. (NASDAQ:CHRS) Shares Sold by Disciplined Growth Investors Inc. MN - MarketBeat

Dec 10, 2024
pulisher
Dec 05, 2024

California-Based Biotech Rallies Strongly Following $558.4M Divestiture - MSN

Dec 05, 2024
pulisher
Dec 05, 2024

Coherus price target raised at Baird on agreement to sell Udenyca - Investing.com Canada

Dec 05, 2024
pulisher
Dec 05, 2024

Coherus BioSciences director Tzoumakas to exit board By Investing.com - Investing.com Canada

Dec 05, 2024
pulisher
Dec 05, 2024

Coherus BioSciences director Tzoumakas to exit board - Investing.com

Dec 05, 2024
pulisher
Dec 05, 2024

Intas acquires Udenyca from Coherus BioSciences in potential $558 million deal - BioProcess Insider

Dec 05, 2024
pulisher
Dec 05, 2024

Coherus BioSciences (FRA:8C5) Price-to-Operating-Cash-Flow : (As of Dec. 05, 2024) - GuruFocus.com

Dec 05, 2024
pulisher
Dec 05, 2024

CHRS (Coherus BioSciences) Price-to-Operating-Cash-Flow : (As of Dec. 05, 2024) - GuruFocus.com

Dec 05, 2024
pulisher
Dec 04, 2024

Coherus Biosciences Announces Board Member Resignation - TipRanks

Dec 04, 2024
pulisher
Dec 04, 2024

Coherus Biosciences' SWOT analysis: stock faces headwinds amid transition By Investing.com - Investing.com Australia

Dec 04, 2024
pulisher
Dec 04, 2024

Latham Watkins Advises Coherus in Divesture of UDENYCA Franchise to Intas Pharmaceuticals - Latham & Watkins LLP

Dec 04, 2024
pulisher
Dec 04, 2024

Accord acquires Coherus’ Udenyca business - The Pharma Letter

Dec 04, 2024
pulisher
Dec 04, 2024

Intas to acquire Coherus’ Udenyca assets for up to $558m - World Pharmaceutical Frontiers

Dec 04, 2024
pulisher
Dec 04, 2024

Goodbye Biosimilars: Coherus Sells Udenyca To Intas For Half A Billion - News & Insights

Dec 04, 2024
pulisher
Dec 04, 2024

S&P 500 Total Return (TCM23) Quote - The Globe and Mail

Dec 04, 2024
pulisher
Dec 04, 2024

Intas Pharma to acquire Udenyca business from Coherus BioSciences - Medical Dialogues

Dec 04, 2024
pulisher
Dec 03, 2024

Coherus Continues Funding IO Ambitions By Offloading Biosimilars - News & Insights

Dec 03, 2024
pulisher
Dec 03, 2024

TSX Consumer Discretionary Capped Index (TTCD) QuotePress Release - The Globe and Mail

Dec 03, 2024
pulisher
Dec 03, 2024

TSX Composite High Beta Index (TXHB) QuotePress Release - The Globe and Mail

Dec 03, 2024
pulisher
Dec 03, 2024

Redwood City-based Coherus' stock surges after major drug sale - The Business Journals

Dec 03, 2024
pulisher
Dec 03, 2024

TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail

Dec 03, 2024
pulisher
Dec 03, 2024

Raleigh pharmaceutical company expands portfolio with $558M deal - The Business Journals

Dec 03, 2024
pulisher
Dec 03, 2024

Coherus, sharpening immuno-oncology focus, sells another biosimilar for over $500M - BioPharma Dive

Dec 03, 2024
pulisher
Dec 03, 2024

Coherus unloads Udenyca in $558M deal to power immuno-oncology ambitions - FirstWord Pharma

Dec 03, 2024
pulisher
Dec 03, 2024

Coherus shares surge on $558M Udenyca divestiture deal By Investing.com - Investing.com South Africa

Dec 03, 2024
pulisher
Dec 03, 2024

Coherus shares surge on $558M Udenyca divestiture deal - Investing.com

Dec 03, 2024
pulisher
Dec 03, 2024

Unusually active option classes on open December 3rd - TipRanks

Dec 03, 2024
pulisher
Dec 03, 2024

Accord BioPharma Announces Agreement by Intas Pharmaceuticals, Ltd. to Acquire UDENYCA® (pegfilgrastim-cbqv) Business from Coherus BioSciences, Inc., Unlocking Potential for Continued U.S. Growth - The Malaysian Reserve

Dec 03, 2024
pulisher
Dec 03, 2024

Why Is Coherus BioSciences Stock Trading Higher On Tuesday? - Inkl

Dec 03, 2024
pulisher
Dec 03, 2024

Coherus Biosciences agrees to divest UDENYCA franchise for up to $558M - TipRanks

Dec 03, 2024
pulisher
Dec 03, 2024

Coherus Bio jumps on deal to divest biosimilar of Amgen's Neulasta - XM

Dec 03, 2024

Finanzdaten der Coherus Biosciences Inc-Aktie (CHRS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$81.01
price up icon 4.02%
$20.62
price up icon 3.20%
$353.43
price down icon 0.32%
$5.09
price down icon 0.20%
biotechnology ONC
$222.91
price down icon 0.21%
$117.14
price down icon 2.24%
Kapitalisierung:     |  Volumen (24h):